Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene

Maturitas

Volumn 48, Issue 3, 2004, Pages 321-327

  Tiitinen, Aila ^a   Nikander, Eini ^a   Hietanen, Päivi ^a   Metsä Heikkilä, Merja ^a   Ylikorkala, Olavi ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Bone mineral density; Tamoxifen; Toremifene

Indexed keywords

ANTIESTROGEN; TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; FEMUR NECK; HORMONE SUBSTITUTION; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DENSITOMETRY, X-RAY; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TOREMIFENE;

EID: 2942687244     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2004.02.018     Document Type: Article

References (20)

1. Holli K., Valavaara R., Blanco G., et al. for the Finnish Breast Cancer Group Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. J. Clin. Oncol. 18:2000;3487-3494
2. Pyrhönen S., Ellmen J., Vuorinen J., et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res. Treat. 56:1999;133-143
3. Grey A.B., Stapleton J.P., Evans M.C., Tatnell M.A., Ames R.W., Reid I.R. The effect of the antiestrogen tamoxifen on bone density in normal late postmenopausal women. Am. J. Med. 99:1995;636-641
4. Love R.R., Mazess R.B., Barden H.S., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 326:1992;852-856
5. Powles T.J., Hickish T., Kanis J.A., Tidy A., Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. 14:1996;78-84
6. Jordan V.G., Gapstur S., Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J. Natl. Cancer Inst. 93:2001;1449-1457
7. Ettinger B., Black D., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 282:1999;637-644
8. Marttunen M.B., Hietanen P., Tiitinen A., Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 83:1998;1158-1162
9. Neele S.J.M., Evertz R., de Valk-de Roo G., Roos J.C., Netelenbos J.C. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone. 30:2002;599-603
10. Kristensen B., Ejlertsen B., Dalgaard P., et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J. Clin. Oncol. 12:1994;992-997
11. Saarto T., Vehmanen L., Elomaa I., Välimäki M., Mäkelä P., Blomqvist C. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br. J. Cancer. 84:2001;1047-1051
12. Turner R.T., Riggs B.L., Spelsberg T.C. Skeletal effects of estrogen. Endocr. Rev. 15:1994;275-300
13. Torgerson D.J., Bell-Syer S.E. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 285:2001;2891-2897
14. Beral V. for the Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 362:2003;419-427
15. Ascott-Evans B.H., Guanabens N., Kivinen S., et al. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Arch. Intern. Med. 163:2003;789-794
16. Ushiroyama T., Ikeda A., Sakai M., Higashiyama T., Ueki M. Prevention of postmenopausal bone loss with exchange for short-term HRT for 1α-hydroxycholecalciferol. Maturitas. 45:2003;119-127
17. Greendale G.A., Espeland M., Slone S., Marcus R., Barrett-Connor E. for the PEPI Safety Follow-up Study Investigators Bone mass response to discontinuation of long-term hormone replacement therapy. Arch. Inter. Med. 162:2002;665-672
18. Callagher J.C., Rapuri P.B., Haynatzki G., Detter J. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J. Clin. Endocrinol. Metab. 87:2002;4914-4923
19. Warming L., Christoffersen C., Riis B.J., Stakkestad J.A., Delmas P.D., Christiansen C. Adverse effects of a SERM (levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal. Maturitas. 44:2003;189-199
20. Lehenkari P., Parikka V., Rautiala T.J., et al. The effects of tamoxifen and toremifene on bone cells involve changes in plasma membrane ion conductance. J. Bone Miner. Res. 18:2003;473-481